Company Overview and News

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities NYSE CERTIFICATION FILING- ING GROEP NV

2018-10-05 sec.gov
begin 644 ING23-23A-288A100518.pdf M)5!$1BTQ+C,*)79E
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 6-K (Current Report of Foreign Issuer)

2018-10-02 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 8-A12B

2018-10-02 sec.gov
8-A12B SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 424B5 (Prospectus)

2018-09-27 sec.gov
424B5 Table of Contents CALCULATION OF REGISTRATION FEE <
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FWP

2018-09-26 sec.gov
FWP Filed pursuant to Rule 433 Dated September 25, 2018 Registration Statement No. 333-227391 Free Writing Prospectus
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 424B5 (Prospectus)

2018-09-25 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-227391 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-09-24 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities F-N

2018-09-18 sec.gov
F-N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-N
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities F-3ASR

2018-09-18 sec.gov
F-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 18, 2018 Registration No. 333-
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-09-11 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-09-05 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 6-K (Current Report of Foreign Issuer)

2018-09-04 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities FORM 6-K (Current Report of Foreign Issuer)

2018-09-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 6-K (Current Report of Foreign Issuer)

2018-08-02 sec.gov
6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
IND

 
IND / ING Groep N.V., 7.05% ING Perpetual Debt Securities 6-K (Current Report of Foreign Issuer)

2018-08-02 sec.gov
6-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
IND

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ISF / ING Groep N.V., 6.375% ING Perpetual Hybrid Capital Securities on message board site Silicon Investor.

Bill Gates is Sharing Hisfortune Bill Gates is Sharing Hisfortune Bill Gates is Sharing Hisfortune Internet Solutions For Business (OTC BB: ISFB) Internet Solutions For Business (OTC BB: ISFB) Internet Solutions For Business (OTC BB: ISFB)
CUSIP: 456837608